Related Experiment Videos
[Fibrillation and atrial flutter. Immediate control and conversion to sinus rhythm with intravenous propafenone]
L Bianconi1, R Boccadamo, A Pappalardo
1Divisione di Cardiologia, Ospedale S. Filippo Neri, Roma.
Giornale Italiano Di Cardiologia
|August 1, 1987
Summary
Intravenous Propafenone effectively converted recent-onset atrial fibrillation (a.f.) or flutter (A.F.) to sinus rhythm in over half of patients. Efficacy was higher when treatment began within 48 hours of arrhythmia onset.
Area of Science:
- Cardiology
- Pharmacology
Context:
- Atrial fibrillation (a.f.) and atrial flutter (A.F.) are common arrhythmias.
- Intravenous antiarrhythmic drug therapy is a treatment option for recent-onset arrhythmias.
Purpose:
- To assess the safety and efficacy of intravenous Propafenone for recent-onset atrial fibrillation or flutter.
Summary:
- Propafenone (2 mg/kg) was administered to 36 patients with recent-onset a.f. or A.F.
- Nineteen patients (52.7%) converted to sinus rhythm, with higher success rates for a.f. (60.7%) compared to A.F. (25%).
- Treatment efficacy was significantly greater when initiated within 48 hours of arrhythmia onset (66.6%) versus later (33.3%).
- Adverse effects included hypotension in two patients. Non-converters experienced a significant reduction in ventricular rate.
Impact:
- Intravenous Propafenone is a potentially effective treatment for recent-onset atrial fibrillation and flutter.
- Early intervention within 48 hours improves treatment outcomes.
- Further research may explore optimal dosing and patient selection for Propafenone therapy.